GL-0001, a first-in-class dual GIP/GLP-2 analogue, reduces bone fragility by enhancing bone material properties in a murine model of type III osteogenesis imperfecta
In the authors' words
Osteogenesis imperfecta (OI) is a severe heritable skeletal disorder characterized by bone fragility, short stature, and increased fracture risk. Currently, no pharmacological treatment has been approved for OI, and bisphosphonates are commonly used off label. While bisphosphonates increase bone mass, their effects on bone quality and fracture reduction remain limited. GL-0001, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-2 (GLP-2) compound that targets bone material properties, may offer alternative skeletal benefits. We evaluated the effects of 9 weeks of GL-0001 treatment in the oim/oim murine model of severe OI, a well-established model carrying a homozygous Col1a2 mutation resulting in abnormal type I collagen formation and compared outcomes with zoledronic acid (100 g/kg) or saline. Analyses included longitudinal growth, fracture incidence, bone biomechanics, microarchitecture, turnover markers, and bone material properties. OI mice exhibited reduced body weight, impaired femoral growth, severe trabecular and cortical deficits, altered bone turnover, and compromised biomechanical properties compared with WT controls. GL-0001 increased femur length by 5% (p=0.015) and reduced spontaneous fracture incidence by 90% (p=0.004), whereas zoledronic acid had no significant effect on fracture burden. Bone microarchitecture was not significantly altered by GL-0001, whereas zoledronic acid improved trabecular and cortical parameters. At the tissue level, GL-0001 improved bone strength, increasing ultimate stress (+26%, p=0.022) and yield stress (+30%, p=0.014), and reducing brittleness (-32%, p=0.002). These changes were associated with increased collagen maturity (+12%, p<0.001). In contrast, zoledronic acid had limited effects on bone material properties. These findings demonstrate that GL-0001 improves skeletal fragility in the oim/oim murine model of severe OI through mechanisms primarily involving enhancement of bone material properties and longitudinal growth, rather than changes in bone mass or microarchitecture. GL-0001 may therefore represent a novel therapeutic strategy targeting bone quality in OI.
In plain words AI summary
Osteogenesis imperfecta is a severe inherited bone disorder that causes fragile bones, short height, and frequent fractures. Researchers tested a new drug called GL-0001 for nine weeks in mice with severe osteogenesis imperfecta. GL-0001 increased thigh bone length by 5% and cut spontaneous fractures by 90%, while a common treatment had no significant effect on fractures. The drug improved bone strength by 26% and made bones less brittle by 32%, linked to more mature collagen. These results suggest GL-0001 may offer a new way to treat osteogenesis imperfecta by improving bone quality rather than bone mass.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Friday, October 23. bioRxiv. Preprint, not yet peer-reviewed.